scholarly journals Immunohistochemical localization of S-100 protein in normal human brain and brain tumors

1984 ◽  
Vol 96 (1-2) ◽  
pp. 197-216 ◽  
Author(s):  
Rinkichi OHNISHI
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Immunohistochemical Localization ◽  
Normal Human Brain ◽  
S 100 ◽  
Normal Human

P-31 MR spectroscopy of normal human brain and brain tumors.

Radiology ◽  
1990 ◽  
Vol 174 (2) ◽  
pp. 401-409 ◽  
Author(s):  
B Hubesch ◽  
D Sappey-Marinier ◽  
K Roth ◽  
D J Meyerhoff ◽  
G B Matson ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Mr Spectroscopy ◽  
Normal Human Brain ◽  
Normal Human

scholarly journals Free magnesium levels in normal human brain and brain tumors: 31P chemical-shift imaging measurements at 1.5 T.

1991 ◽  
Vol 88 (15) ◽  
pp. 6810-6814 ◽  
Author(s):  
J. S. Taylor ◽  
D. B. Vigneron ◽  
J. Murphy-Boesch ◽  
S. J. Nelson ◽  
H. B. Kessler ◽  
...  
Keyword(s):  
Chemical Shift ◽  
Brain Tumors ◽  
Human Brain ◽  
Chemical Shift Imaging ◽  
Normal Human Brain ◽  
Normal Human ◽  
Free Magnesium

Cellular Localization of Endothelin Receptor mRNAs (ETA and ETB) in Brain Tumors and Normal Human Brain

1995 ◽  
Vol 26 ◽  
pp. S104-106
Author(s):  
Uberto Pagotto ◽  
Thomas Arzberger ◽  
Ursula Hopfner ◽  
Adolf Weindl ◽  
Günter K. Stalla
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Cellular Localization ◽  
Endothelin Receptor ◽  
Normal Human Brain ◽  
Normal Human ◽  
Receptor Mrnas

Cellular Localization of Endothelin Receptor mRNAs (ETA and ETB) in Brain Tumors and Normal Human Brain

1995 ◽  
Vol 26 ◽  
pp. S104-106 ◽  
Author(s):  
Uberto Pagotto ◽  
Thomas Arzberger ◽  
Ursula Hopfner ◽  
Adolf Weindl ◽  
Günter K. Stalla
Keyword(s):  
Brain Tumors ◽  
Human Brain ◽  
Cellular Localization ◽  
Endothelin Receptor ◽  
Normal Human Brain ◽  
Normal Human ◽  
Receptor Mrnas

Astroglial growth factors in normal human brain and brain tumors: comparison with embryonic brain

1992 ◽  
Vol 12 (3) ◽  
pp. 205-218 ◽  
Author(s):  
Michel P. Rathbone ◽  
Galina K. Szlapetis ◽  
Rocco de Villiers ◽  
Rolando F. Del Maestro ◽  
Joseph Gilbert ◽  
...  
Keyword(s):  
Growth Factors ◽  
Brain Tumors ◽  
Human Brain ◽  
Embryonic Brain ◽  
Normal Human Brain ◽  
Normal Human

The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma

2006 ◽  
Vol 104 (4) ◽  
pp. 583-592 ◽  
Author(s):  
Winan J. Van Houdt ◽  
Yosef S. Haviv ◽  
Baogen Lu ◽  
Minghui Wang ◽  
Angel A. Rivera ◽  
...  
Keyword(s):  
Gene Expression ◽  
Brain Tumors ◽  
Human Brain ◽  
Cell Lines ◽  
Reporter Gene ◽  
Transcriptional Targeting ◽  
Survivin Promoter ◽  
Normal Human Brain ◽  
Apoptosis Protein ◽  
Normal Human

Object Malignant brain tumors have been proved to be resistant to standard treatments and therefore require new therapeutic strategies. Survivin, a recently described member of the inhibitor of apoptosis protein family, is overexpressed in several human brain tumors, primarily gliomas, but is downregulated in normal tissues. The authors hypothesized that the expression of tumor-specific survivin could be exploited for treatment of gliomas by targeting the tumors with gene therapy vectors. Methods Following confirmation of survivin expression in glioma cell lines, an adenoviral vector containing the survivin promoter and the reporter gene luciferase was tested in established and primary glioma cells, normal astrocytic cells, and normal human brain tissues. High levels of reporter gene expression were observed in established tumor and primary tumor cell lines and low levels of expression in astrocytes and normal human brain tissue. To test oncolytic potency, the authors constructed survivin promoter–based conditionally replicative adenoviruses (CRAds), composed of survivin promoter–regulated E1 gene expression and an RGD-4C capsid modification. These CRAds could efficiently replicate within and kill a variety of established glioma tumor cells, but were inactive in a normal human liver organ culture. Finally, survivin promoter–based CRAds significantly inhibited the growth of glioma xenografts in vivo. Conclusions Together these data indicate that the survivin promoter is a promising tumor-specific promoter for transcriptional targeting of adenovirus-based vectors and CRAds for malignant gliomas. The strategy of using survivin–CRAds may thus translate into an experimental therapeutic approach that can be used in human clinical trials.

Sign in / Sign up

Export Citation Format

Share Document